These price increases above the inflation “has not happened since 2019”, chen annual inflation of 53.8% and an increase in the value of medicines of 111.9% was recorded, Ceprofar said today in a statement.
Likewise, he specified that the Annual CPI 2023 was 222.7% and he clarified that to reach that figure he took the December estimate (30%).
Meanwhile, in the last two months of last year (from November 1 to December 31), “the average increase in medications was 90%, exceeding 100% in some cases of widely used medications,” the entity noted.
It also contemplated that in November-December 2023, price regulation was no longer in effect, through agreements between the Government and the laboratories, which ended on October 31.
“Until that moment, prices had accompanied -in general terms- inflation”he stressed.
Price increases: what is the concern of the pharmaceutical sector
On the other hand, Ceprofar stated that “with this level of increases, the possibility of problems in coverage through the social works, who have their income in relation to the salaries of its members”.
“There is also concern about the possibility that the free delivery of medicines through PAMI, which today benefits nine out of every 10 retirees,” he added.
Price increases: which are the medicines with the biggest gaps
In this sense, the report warned that “large differences are observed between the prices of different brands of medicines widely used, such as omeprazole (antiulcer), losartan (antihypertensive), clopidogrel (antithrombotic), paracetamol (analgesic), ciprofloxacin (antibiotic), ibuprofen (analgesic), salbutamol (bronchodilator) and enalapril (antihypertensive), among others.
“This is explained by the low compliance and poor dissemination of Law 25,649 on prescription by generic name and for the inclusion of commercial brands in the recipes, in favor of the more expensive brands, without foundation,” the pharmaceutical entity awarded.
Source: Ambito
